Castle Biosciences, Inc. (CSTL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Castle Biosciences, Inc. (CSTL) is down 49.3% since the beginning of the year. At $20 per share, CSTL is trading 55.5% below its 52-week high of $44. Investors who bought $1,000 worth of CSTL shares 5 years ago would now be looking at an investment worth $332.

Castle Biosciences, Inc. (CSTL) has returned -49.33% so far this year and 17.95% over the past 12 months.

Based on dividend-adjusted daily data since Jul 25, 2019, CSTL's average daily return is +0.11%, while the average monthly return is +1.76%. At this rate, an investment would double in approximately 3.3 years.

Historically, 48% of months were positive and 52% were negative. The best month was Aug 2025 with a return of +58.5%, while the worst month was Apr 2022 at -50.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, CSTL closed higher 49% of trading days. The best single day was Jul 7, 2023 with a return of +52.9%, while the worst single day was Jun 5, 2023 at -48.7%.

Castle Biosciences, Inc. has an annualized alpha of 10.25%, beta of 1.08, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since July 26, 2019.

• This stock participated in 153.02% of S&P 500 Index downside but only 97.91% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CSTL ranks 52 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Castle Biosciences, Inc. (CSTL) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Castle Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Castle Biosciences, Inc. was 88.02%, occurring on Jun 5, 2023. The portfolio has not yet recovered.

The current Castle Biosciences, Inc. drawdown is 79.75%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Castle Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Castle Biosciences, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.